Table 3.

 EGFR and HER2 protein expression in AAH and adenocarcinoma of the lung

Parameter	Adenocarcinoma				p Value	Total (n = 86)
	AAH (n = 14)	BAC (n = 31)	Early MX (n = 22)	Overt MX (n = 33)
EGFR	0	1 (3.2%)	8 (36.4%)	15 (45.6%)	<0.0001	24 (27.9%)
HER2	0	1 (3.2%)	6 (27.3%)	11 (33.3%)	0.0034	18 (20.9%)
Synchronous expression pattern	–	1 (10%)	3 (30%)	6 (60%)	<0.0001	10 (11.6%)

The Kruskal Wallis test was used to assess the p values among BAC, early MX, and overt MX.

AAH, atypical adenomatous hyperplasia; BAC, bronchioloalveolar carcinoma; EGFR, epidermal growth factor receptor; MX, adenocarcinoma with mixed subtypes.